| Media Search: |
revolution slider za header word press tutorial
Dodavanje frejmova-slika u revolution slider za Word press header-zaglavlje... Svaka strana moze imati svoj header ili jednu ili 5 slika kako odredimo... Pos...
By: Lazic Nenad
View original post here:
revolution slider za header word press tutorial - Video
DGAP-News: Leifheit AG / Key word(s): Development of Sales/Product Launch Leifheit AG: Preliminary figures for 2013 show slight growth
06.02.2014 / 10:00
=--------------------------------------------------------------------
PRESS RELEASE
Leifheit: Preliminary figures for 2013 show slight growth
- Adjusted group turnover rises 1.0% - Brand Business grows, Volume Business remains stable - At 27.7% E-Commerce sales channel continues to achieve high growth rates - In 2014 Leifheit is concentrating on brands and margin
Nassau, 6 February 2014 - According to preliminary calculations, the Leifheit Group achieved adjusted sales totalling EUR 219.5 million in the financial year 2013, an increase of 1.0% on the previous year. Without the adjustment of the terminated business with Dr Oetker Bakeware, group turnover is expected to be EUR 220.9 million.
Whilst in the financial year of 2013 demand in the domestic market of Germany remained stable, satisfactory growth rates in Leifheit's Central European focus countries of France, Austria, Czech Republic and Scandinavia were the reason behind the slightly positive turnover development in the Leifheit Group. In contrast, decreases in demand slowed business development in the Netherlands, Italy and Russia.
Brand Business +1.1%, Volume Business +0.4%
In 2013, the Brand Business, the larger of the two Leifheit business areas, grew 1.1% on the previous year with a turnover of EUR 172.8 million. This area includes the brands Leifheit and Soehnle. In the volume business segment, in which the activities of the subsidiaries Birambeau and Herby as well as the Project Business are bundled, the preliminary figures for 2013 show a turnover increase of 0.4% to EUR 46.7 million.
Read this article:
PRESS RELEASE: Leifheit AG: Preliminary figures for 2013 show slight growth
DGAP-News: MOLOGEN AG / Key word(s): Capital Increase MOLOGEN AG resolves capital increase from authorized capital
05.02.2014 / 21:53
=--------------------------------------------------------------------
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA.
MOLOGEN AG resolves capital increase from authorized capital
With the approval of the Supervisory Board and on the basis of the registered authorized capital the Management Board of MOLOGEN AG decided today to increase the share capital against cash contributions without subscription rights of the shareholders from currently EUR 15,419,512 to EUR 16,960,756 by issuing up to 1,541,244 new no-par value bearer shares with dividend rights from 1st January 2013. The proceeds from the capital increase will be used to further strengthen the equity base and in particular to finance the development of the product pipeline and the necessary ongoing research operations.
The new shares will be offered to European qualified investors in the context of a private placement. quirin bank AG, Berlin, accompanies the transaction as lead manager and bookrunner.
The placement starts today, 5 February 2014, and is expected to be completed tomorrow, 6 February 2014. MOLOGEN AG will set the issue price after the completion of a bookbuilding process and depending on the market situation at a discount of up to 5 per cent on the volume weighted average share price in Xetra trading during the last five trading days or on the in XETRA trading lastly determined stock price. The new shares shall be admitted to trading, without prospectus requirement, in the sub-segment of the regulated market with further post-admission obligations (Prime Standard) of the Frankfurt Stock Exchange
Disclaimer:
This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities.
Link:
PRESS RELEASE: MOLOGEN AG resolves capital increase from authorized capital
PRESS RELEASE: MOLOGEN AG: Successful capital increase enables phase III study with immunotherapy MGN 1703 (colon cancer)
DGAP-News: MOLOGEN AG / Key word(s): Capital Increase MOLOGEN AG: Successful capital increase enables phase III study with immunotherapy MGN 1703 (colon cancer)
06.02.2014 / 17:27
=--------------------------------------------------------------------
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA.
PRESS RELEASE N 02 / 2014 of 02/06/2014
MOLOGEN AG: Successful capital increase enables phase III study with immunotherapy MGN 1703 (colon cancer)
Berlin, February 6, 2014 - MOLOGEN AG has successfully concluded the capital increase, which was resolved yesterday. The issue price was set at EUR 10.20 per new share. In the context of a private placement the capital increase was fully placed with qualified investors in the amount of 1,541,244 shares (equivalent to 10 per cent of the current share capital). The share capital will therefore be increased by issuing 1,541,244 new no-par value bearer shares from currently 15,419,512 Euros to then 16,960,756 Euros. The gross proceeds amount to approximately 15.7 million Euros.
The proceeds from the capital increase will be used to further strengthen the equity base as well as to finance the development of the product pipeline and the proceeds enable in particular to start the planned pivotal clinical phase III study with MGN1703 in metastatic colorectal cancer.
Dr. Matthias Schroff, CEO of MOLOGEN AG: 'The planning for the pivotal study has been largely completed. Thus, our cancer immunotherapy MGN1703 can enter into the final clinical phase this year in order to confirm the previous excellent results in a significantly larger number of patients. We are delighted about the trust of the investors.'
DGAP-News: Nordex SE / Key word(s): Incoming Orders Nordex awarded further major contract by Taaleritehdas:
06.02.2014 / 09:02
=--------------------------------------------------------------------
19 turbines called down under the frame contract for Finland's largest wind power project
Hamburg, 6 February 2014. Finnish Investment company Taaleritehdas has placed another large-scale order with Nordex for a further 19 N117/2400 turbines, which are to be supplied for the Myllykangas wind farm on the northwest coast of Finland. This marks Taaleritehdas' third calldown under the frame contract, which was signed in 2012 for a total of up to 111 turbines. It has already acquired 17 Nordex turbines specially developed for IEC-3 wind classes for the Honkajoki and Nyby-li sites.
Myllykangas is located not far from the Nybi-li wind farm in the Ii region, where eight wind turbines are currently under construction. Accordingly, Nordex will also be providing service for the 19 turbines under the current calldown from the joint service point in Kempele. With a nominal output of 2.4 megawatts each and a hub height of 120 meters, the turbines will be supplied in the cold-climate version from autumn 2014 and are scheduled to be connected to the grid in 2015. Myllykangas will be Finland's largest wind farm and form a single cluster together with Nyby-Li.
'We are pleased to see that our business in Finland continues to develop well and that Taaleritehdas chooses Nordex again', says Lars Bondo Krogsgaard, member of the Nordex SE Management Board.
'We are very pleased to continue our good co-operation with Nordex now in Myllykangas. We have very good experience of Nordex N117 turbines from our Honkajoki site and therefore feel confident in continuing to install Nordex turbines in our next development site in Myllykangas, Ii', says Taamir Fareed, Director of Taaleritehdas Wind Energy Operations.
Together with the projects Nyby-Ii, Mkikangas and Joukhaisselk Nordex will be installing more than 40 turbines with a total capacity of 125 MW in Finland.
About Nordex As one of the technological leaders in multi-megawatt wind power systems, Nordex is benefiting from the trend in favour of large-scale turbines. The Generation Gamma range comprises the N90/2500, N100/2500 and the N117/2400, which is one of the most efficient series turbines for non-coastal regions. To date, over 2,600 of these turbines have been produced. This experience with multi-megawatt turbines gives Nordex a decisive lead over most of its competitors. With Generation Delta, Nordex is now offering the fourth generation of its proven multi-megawatt platform (N100/3300, N117/3000, N131/3000). Nordex has installed a total of over 5,600 turbines with an aggregate capacity of around 9,400 MW all around the world. With exports accounting for more than 85 percent of its business, Nordex SE plays a key role in international high-growth regions. The Company has offices and subsidiaries in 22 countries around the world with a total global headcount of over 2,500 employees.
Go here to see the original:
PRESS RELEASE: Nordex awarded further major contract by Taaleritehdas: